GE Healthcare, Wauwatosa, Wis, announced on September 3 the FDA approval of GE’s SenoClaire breast tomosynthesis system. Designed with a 3D imaging technology, the system uses a low-dose short x-ray sweep around the positioned breast with nine exposures acquired using a “step-and-shoot” method. This approach, GE says, removes the potential motion from the tube, thus helping to reduce blur and increase image sharpness.
“3D breast screening technology helps clinicians uncover small cancers which can be a limiting factor in standard 2D mammography. As a radiologist, it’s important to offer technology like this for patients that produces higher image quality without increasing dose,” Murray Rebner MD, said in a press release. “We believe this technology can have a significant impact on helping clinicians to identify breast cancer.” Rebner is a professor at Oakland University William Beaumont School Of Medicine, and director of the division of breast imaging and intervention at Beaumont Hospital, Royal Oak, Mich.
SenoClaire is compatible with Centricity PACS with Universal Viewer and supports the DICOM standard that can be read by capable PACS vendors. When SenoClaire is combined with GE Healthcare’s Centricity PACS and Centricity Clinical Archive solution, the company says, clinicians have access to the patient’s longitudinal record.
For more information on SenoClaire, visit GE Healthcare’s website.